Open an account

Monopar Therapeutics

MNPR · NASDAQ

$74.23+$2.76 (+3.86%)TodayMarket closed ·
Prev close $71.47

About MNPR

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 22 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Employees
22
Headquarters
Wilmette, Illinois
Listed
Dec 19, 2019
Sector
Health Care
Industry
Biotechnology
Website
monopartx.com

MNPR key statistics

Market cap
498.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
150.66K
Volume
89.54K
Open price
$72.20
High today
$74.90
Low today
$71.95
52 Week high
$124.82
52 Week low
$50.07

Monopar Therapeutics (MNPR) at a glance

Monopar Therapeutics (MNPR) last traded at $74.23, with a market cap of 498.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $71.95 and $74.90. The current price is 3.2% above the day's low and 0.9% below its high.

Volume so far is 89.54K shares, below the average of 150.66K shares a day.

Over the past year Monopar Therapeutics has ranged from $50.07 to $124.82, and now sits 32% of the way up that range.

Monopar Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.62 per share against an estimate of -$0.6335.

The average analyst price target is $130.17, 75.4% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 15 analystsAvg $130.17
Low
$101.00
Now
$74.23
High
$152.25

MNPR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 28.9% on average.

  1. Q3 FY24: reported -$0.37 per share against an estimate of -$0.4862
  2. Q4 FY24: reported -$2.75 per share against an estimate of -$0.4284
  3. Q1 FY25: reported -$0.38 per share against an estimate of -$0.6936
  4. Q2 FY25: reported -$0.35 per share against an estimate of -$0.4814
  5. Q3 FY25: reported -$0.48 per share against an estimate of -$0.4386
  6. Q4 FY25: reported -$0.64 per share against an estimate of -$0.5028
  7. Q1 FY26: reported -$0.46 per share against an estimate of -$0.8521
  8. Q2 FY26: reported -$0.62 per share against an estimate of -$0.6335

MNPR news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releasePRNewswire

    Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Avi Kapoor

    Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Avi Kapoor

    Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Monopar Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.